Teleflex (NYSE:TFX) Given New $191.00 Price Target at Morgan Stanley

Teleflex (NYSE:TFX) had its price target cut by Morgan Stanley from $275.00 to $191.00 in a research note published on Wednesday,Benzinga reports. They currently have an overweight rating on the medical technology company’s stock.

Several other research analysts also recently weighed in on the stock. StockNews.com downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Royal Bank of Canada downgraded shares of Teleflex from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $220.00 to $155.00 in a research note on Friday, February 28th. Citizens Jmp downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Wells Fargo & Company decreased their target price on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Finally, Bank of America downgraded shares of Teleflex from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $235.00 to $140.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $182.63.

Teleflex Price Performance

TFX opened at $134.38 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex has a 52-week low of $128.55 and a 52-week high of $249.90. The company has a 50 day moving average of $172.79 and a two-hundred day moving average of $202.69. The company has a market cap of $6.24 billion, a P/E ratio of 26.71, a P/E/G ratio of 1.73 and a beta of 1.16.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.86 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. On average, analysts expect that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, March 7th will be issued a $0.34 dividend. The ex-dividend date is Friday, March 7th. This represents a $1.36 annualized dividend and a yield of 1.01%. Teleflex’s dividend payout ratio is presently 95.77%.

Institutional Trading of Teleflex

Several institutional investors have recently added to or reduced their stakes in the stock. Avior Wealth Management LLC raised its holdings in shares of Teleflex by 190.6% during the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 101 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Teleflex during the third quarter worth $40,000. Headlands Technologies LLC acquired a new stake in shares of Teleflex during the fourth quarter worth $29,000. True Wealth Design LLC raised its holdings in shares of Teleflex by 16,600.0% during the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 166 shares during the period. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Teleflex during the third quarter worth $54,000. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.